Tvardi Therapeutics (NASDAQ:TVRD) Raised to Strong-Buy at Lucid Cap Mkts

Tvardi Therapeutics (NASDAQ:TVRD) was upgraded by investment analysts at Lucid Cap Mkts from a “hold” rating to a “strong-buy” rating in a note issued to investors on Wednesday,Zacks.com reports.

TVRD has been the topic of a number of other reports. Barclays set a $5.00 price objective on Tvardi Therapeutics and gave the company an “equal weight” rating in a research report on Monday, October 13th. Cantor Fitzgerald downgraded shares of Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday, October 13th. Weiss Ratings reissued a “sell (e)” rating on shares of Tvardi Therapeutics in a research note on Monday, December 29th. Raymond James Financial cut shares of Tvardi Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, October 14th. Finally, BTIG Research dropped their target price on shares of Tvardi Therapeutics from $55.00 to $15.00 and set a “buy” rating for the company in a report on Monday, October 13th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Tvardi Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $55.50.

Tvardi Therapeutics Stock Performance

Shares of NASDAQ:TVRD opened at $3.55 on Wednesday. The stock’s 50-day simple moving average is $4.21 and its two-hundred day simple moving average is $15.53. The stock has a market capitalization of $33.30 million, a price-to-earnings ratio of -0.37 and a beta of 0.14. Tvardi Therapeutics has a 52-week low of $3.50 and a 52-week high of $43.65.

Tvardi Therapeutics (NASDAQ:TVRD) last announced its earnings results on Thursday, November 13th. The company reported ($0.59) EPS for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.24.

Institutional Trading of Tvardi Therapeutics

Several hedge funds have recently bought and sold shares of TVRD. JPMorgan Chase & Co. bought a new position in shares of Tvardi Therapeutics during the 2nd quarter valued at about $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Tvardi Therapeutics in the second quarter worth about $43,000. Headlands Technologies LLC purchased a new stake in shares of Tvardi Therapeutics in the second quarter worth about $80,000. New York State Common Retirement Fund bought a new position in Tvardi Therapeutics during the second quarter valued at approximately $92,000. Finally, Squarepoint Ops LLC purchased a new position in Tvardi Therapeutics during the 3rd quarter valued at approximately $318,000. Hedge funds and other institutional investors own 44.66% of the company’s stock.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.